N-Heterocyclic GPCR Receptor Agonists, Pharmaceutical Compositions Containing the Same, and Methods of Using the Same

Abstract

This specification provides GLP-1 receptor modulator compounds, pharmaceutical compositions, methods for their preparation, and methods for their use in treatment and / or diagnosis.

Description

Technical Field

[0001] This specification provides GLP-1 receptor modulator compounds, pharmaceutical compositions containing the compounds, methods for manufacturing the compounds, and methods for using the compounds and compositions for treatment. The compounds and compositions are useful, for example, in methods for treating and preventing metabolic diseases or conditions, methods for detecting metabolic diseases or conditions, and methods for diagnosing metabolic diseases or conditions.

Background Art

[0002] Diabetes is a serious chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Complications of diabetes include damage to the heart, blood vessels, eyes, kidneys, and nerves. Diabetes can increase the risk of heart disease and stroke. The consequences include serious impacts on quality of life, health, and mortality. WHO Global Report on Diabetes, 2016, World Health Organization. As of 2017, approximately 462 million people worldwide, about 6.28% of the population, had type 2 diabetes, and this prevalence is visibly increasing. Khan et al., 2020, J. Epidemiol. Glob. Health 10(1):107-111. The global economic burden of diabetes in 2015 was estimated at $1.3 trillion and is projected to increase to $2.1 trillion by 2030. Bommer et al., 2018, Diabetes Care 41(5):963-970. Approximately 90-95% of all diabetes cases are type 2 diabetes. Tripathi & Srivastava, 2016, Med. Sci. Monit. 12(7):RA130-147.

[0003] Glucagon-like peptide-1 receptor (GLP-1 receptor, or GLP1R) has emerged as a potential target for treating type 2 diabetes. Its ligand, glucagon-like peptide-1 (GLP-1), among many other effects, promotes glucose-induced insulin secretion and increases insulin synthesis. Doyle and Egan, 2007, Pharmacol. Ther. 113(3):546-593. GLP-1 is known to delay gastric emptying, suppress food intake, enhance satiety, and reduce body weight in humans. Shah and Vella, 2014 Rev Endocr Metab Disord. 15(3):181-187. Activation of the GLP-1 receptor has been shown to have beneficial effects on insulin secretion and on the maintenance of glucose sensing, transcription, synthesis, proliferation, and survival of beta cells. Doyle and Egan, 2007 (supra). Although the GLP-1 receptor is a promising therapeutic target, only a handful of GLP-1 receptor pharmaceuticals have been approved to date, and most or all of these are peptide or polypeptide pharmaceuticals.

[0004] Additional treatments are needed to treat metabolic diseases and conditions such as type 2 diabetes. Small molecules that target the GLP-1 receptor should provide safe, stable, and easily administered therapeutics for metabolic diseases and conditions such as type 2 diabetes. SUMMARY OF THE INVENTION

[0005] This specification provides GLP-1 receptor modulator compounds of formulae (LVII)-(LXIV) and their sub-formulae, compositions comprising the compounds, methods of making the compounds, and methods of using the compounds, and compositions in treatment and diagnosis. Compounds of formulae (LVII)-(LXIV), and embodiments thereof, are useful for modulating the activity of the GLP-1 receptor. In certain embodiments, the compounds can be used to agonize the activity of the GLP-1 receptor. In certain embodiments, the compounds can be used to treat diseases or conditions modulated by the GLP-1 receptor.

[0006] In one aspect, compounds of formula (LVII), (LVIII), (LIX), (LX), (LXI), or (LXII), and compounds 552, 553, 561, 562, 572, 573, 576, 578, 581, 640, and 641, or pharmaceutically acceptable salts or stereoisomers thereof are provided:

Chem.

[0007] In certain embodiments, when the compound is as described in formula (LVII), B 4 is -CH-, -C(R 2 )-, or -N-, D 1 is -CH- or -N-, D 2 is -CH-, -N-, -C(CH3)-, D 4 is -CH- or -N-, W is N, CR 14 , or C, and when W is CR 14 , the adjacent dashed line represents a single bond, and when W is C, the adjacent dashed line represents a double bond or L 2 is -C(H)=, L 1 is selected from the group consisting of -O-, -CH2-, -NH-, -N(Me)-, -N(Et)-, -OCH2-, -OC(H,Me)-, -CH2O-, -NHCH2-, -CH2NH-, -N(Me)CH2-, and -SO2NH-, L 2 is a bond, -C(O)-, -CH2-, -C(H)=, SO2-, -O-, -NH-, -N(Me)-, and

Chem.

Chemical formula

[0008] In certain embodiments, when the compound is as described in formula (LVIII), R 3 is independently selected from the group consisting of -CH2CH3, -CH2F, -CH2CN, and -CF3, and all other variables are as in formula (LVII), and B 4 is -C-, and R 3 is -CH2F, the compound is

Chemical formula

Chemical formula

[0009] In certain embodiments, when the compound is as described in formula (LIX), the variables are as in formula (LVII).

[0010] In certain embodiments, when it is as described in formula (LX), R 4 is selected from the group consisting of (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl,

Chemical formula

[0011] In certain embodiments, the compound is as described in formula (LXI), and all other variables are as in formula (LVII).

[0012] In certain embodiments, when the compound is as described in formula (LXII), it is any one of (a), (b), (c), (d), or (e), (a) D 1 is -N-, and D 2 and D 4 is -CH-, the compound is not one of the following compounds. [Table 1] All other variables are as in formula (LVII), or (b) D 1 and D 4 are -CH-, D 2 is -N-, and all other variables are as in formula (I), or (c) D 1 is -CH-, D 4 is -CH- or -N-, D 2 is -C(CH3), and all other variables are as in formula (LVII), or (d) D 1 , D 2 , and D 4 are -CH- or -N-, D 1 , D 2 , and D 4 of which 0 or 1 is -N-, R 5 is -H, -CH2OH, -CH2COOH, -(CH2)2COOH, [Chemical formula] selected from the group consisting of, R 13 is -CH3 or -cyclopropyl, and all other variables are as in formula (LVII), or (e) D 1 , D 2 , and D 4 are -CH- or -N-, D1 , D 2 , and D 4 Of these, 0 or 1 is -N-, and L 3 is -CH(CH3)-, and all other variables are as in formula (LVII).

[0013] In certain embodiments, compounds 552, 553, 558, 561, 562, 572, 573, 576, 578, 581, 590, and 591 are provided.

Table 2-1

Table 2-2

Table 2-3

[0014] In certain embodiments, when the compound is as described in formula (LVII), (LVIII), (LIX), (LX), or (LXII), L 1 is selected from the group consisting of -NH-, -N(Me)-, -N(Et)-, -OCH2-, -OC(H,Me)-, -CH2O-, -OCH2(cyclopropyl)-, -O-CH2-CH2-, -CH2-O-CH2-, -CH2-O-C((CH3)2), -NHCH2-, -N(Me)CH2-, and -SO2NH-.

[0015] In one aspect, there is provided a compound as described in formula LXIII, or a pharmaceutically acceptable salt or stereoisomer thereof,

Chemical Structure

Chemical formula

[0016] In one aspect, there is provided a compound according to formula LXIV, or a pharmaceutically acceptable salt or stereoisomer thereof, [Chemical] wherein D 1 is -CH- or -N-, D 2 is -CH-, -N-, -C(CH3)-, D 4 is -CH- or -N-, W is N, CR 14 , or C, where W is CR14 When it is, adjacent dashed lines indicate single bonds, and when W is C, adjacent dashed lines indicate double bonds, or L 2 is -C(H)=, L 1 is selected from the group consisting of -O-, -CH2-, -NH-, -N(Me)-, -N(Et)-, -OCH2-, -OC(H,Me)-, -CH2O-, -NHCH2-, -CH2NH-, -N(Me)CH2-, and -SO2NH- L 2 is a bond, -C(O)-, -CH2-, -C(H)=, SO2-, -O-, -NH-, -N(Me)-, and

Chemical formula

Chem.

[0017] In certain embodiments, the compounds are useful in methods for treating and preventing metabolic diseases and conditions, methods for detecting metabolic diseases and conditions, and methods for diagnosing metabolic diseases and conditions.

[0018] In another embodiment, compositions comprising compounds of Formulas (LVII)-(LXIV) are provided. In some embodiments, the composition is a pharmaceutical composition. Any suitable pharmaceutical composition can be used. In a further embodiment, kits comprising a compound of Formulas (LVII)-(LXIV), or an embodiment thereof, or a pharmaceutical composition thereof are provided herein.

[0019] In another embodiment, methods of using the compounds or compositions described herein are provided herein. In some embodiments, the method is for treatment. In some embodiments, the method is a diagnostic method. In some embodiments, the method is an analytical method. In some embodiments, the compounds or compositions described herein are used to treat a disease or condition. In some embodiments, the disease or condition is selected from metabolic diseases or conditions. In certain embodiments, the disease is type 2 diabetes.

[0020] Also provided herein is the use of the compounds and compositions thereof described herein for the treatment of metabolic diseases or conditions. Also provided herein is the use of the compounds and compositions thereof described herein for the treatment of type 2 diabetes.

DETAILED DESCRIPTION OF THE INVENTION

[0021] Described herein are GLP-1 receptor compounds useful for the treatment of metabolic diseases or conditions such as type 2 diabetes.

[0022] Definitions Unless otherwise defined, all technical terms, notations, and other scientific and technical terms used herein shall have the meanings commonly understood by those of ordinary skill in the art to which this disclosure pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference. The methods and procedures described or referred to herein are generally well understood and commonly used by those of ordinary skill in the art using conventional methodologies. Procedures involving the use of commercially available kits and reagents are generally carried out in accordance with the protocols and conditions set forth by the manufacturer, unless otherwise specified.

[0023] As used herein, unless the context clearly dictates otherwise, the singular forms “a,” “an,” and “the” include plural referents.

[0024] The term “about” refers to and encompasses the indicated value and the range above and below that value. In certain embodiments, the term “about” indicates the specified value ±10%, ±5%, or ±1%. In certain embodiments, the term “about” indicates the specified value ± one standard deviation of that value. In certain embodiments, for example, on a logarithmic scale (e.g., pH), the term “about” indicates the specified value ±0.3, ±0.2, or ±0.1.

[0025] When referring to the compounds provided in this specification, the following terms have the following meanings unless otherwise indicated. Unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as commonly understood by those skilled in the art. If there are multiple definitions for the terms in this specification, the definitions in this section shall prevail unless otherwise stated.

[0026] "Alkoxy" and "alkoxyl" refer to an -OR" group, where R" is alkyl or cycloalkyl. As alkoxy groups, in certain embodiments, there may be mentioned methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, etc.

[0027] The term "alkoxyamine" as used in this specification refers to an -alkylene-O-NH2 group, where alkylene is as defined herein. In some embodiments, the alkoxyamine group may react with an aldehyde to form an oxime residue. Examples of alkoxyamine groups include -CH2CH2-O-NH2 and -CH2-O-NH2.

[0028] The term "alkyl" as used in this specification refers to a saturated straight-chain or branched hydrocarbon, unless otherwise explicitly stated. In certain embodiments, the alkyl group is a primary, secondary, or tertiary hydrocarbon. In certain embodiments, the alkyl group contains 1 to 10 carbon atoms (i.e., C1-C 10 alkyl). In certain embodiments, alkyl is lower alkyl, for example, C 1-6Such as alkyl. In certain embodiments, the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl. In certain embodiments, "substituted alkyl" refers to alkyl substituted with one, two, or three groups independently selected from halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, alkoxy, aryl, heteroaryl, cycloalkyl, cyano, oxo, alkyne, and heterocycloalkylalkylene. In some embodiments, the alkyl is unsubstituted.

[0029] As used herein, the term "alkylene" refers to a divalent alkyl group as defined herein, unless otherwise specified. "Substituted alkylene" refers to an alkylene group substituted as described herein for alkyl. In some embodiments, the alkylene is unsubstituted.

[0030] In certain embodiments, "alkenyl" refers to an olefinically unsaturated hydrocarbon group that can be linear or branched, has up to about 11 carbon atoms, or 2-6 carbon atoms (e.g., "lower alkenyl"), and has at least one, or 1-2 olefinically unsaturated sites. "Substituted alkenyl" refers to an alkenyl group substituted as described herein for alkyl.

[0031] "Alkenylene" refers to a divalent alkenyl as defined herein. Lower alkenylene is, for example, C2-C6-alkenylene.

[0032] In certain embodiments, "alkynyl" refers to an acetylenically unsaturated hydrocarbon group that can be linear or branched, has up to about 11 carbon atoms, or 2 - 6 carbon atoms (e.g., "lower alkynyl"), and has at least one, or 1 - 2 acetylenic unsaturation sites. Non-limiting examples of alkynyl groups include acetylene (-C≡CH), propargyl (-CH2C≡CH), and the like. "Substituted alkynyl" refers to an alkynyl group substituted as described herein for alkyl.

[0033] "Alkynylene" refers to a divalent alkynyl as defined herein. Lower alkynylene is, for example, C2-C6-alkynylene.

[0034] "Amino" refers to -NH2.

[0035] As used herein, the term "alkylamino" refers to an -NHR” group, where R” is, for example, C 1-10 alkyl as defined herein, unless otherwise specified. In certain embodiments, alkylamino is C 1-6 alkylamino.

[0036] As used herein, the term "dialkylamino" refers to an -NR”R” group, where each R” is independently C 1-10 alkyl as defined herein, unless otherwise specified. In certain embodiments, dialkylamino is di-C 1-6 alkylamino.

[0037] As used herein, the term "aryl", unless otherwise expressly indicated, refers to phenyl, biphenyl, or naphthyl. This term includes both substituted and unsubstituted moieties. An aryl group may be substituted with one or more moieties (e.g., in some embodiments, 1, 2, or 3 moieties) selected from the group consisting of halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate, but is not limited thereto, where, as will be understood by those skilled in the art, each moiety is independently optionally protected or protected as necessary (e.g., Greene et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991), and the aryl in arylamino and aryloxy substituents is further unsubstituted.

[0038] As used herein, the term "arylamino", unless otherwise expressly indicated, refers to an -NR’R” group, where R’ is hydrogen or C1-C6-alkyl and R” is aryl as defined herein.

[0039] As used herein, the term "arylene", unless otherwise expressly indicated, refers to a divalent aryl group as defined herein.

[0040] As used herein, the term "aryloxy", unless otherwise expressly indicated, refers to an -OR group, where R is aryl as defined herein.

[0041] "Alkarylene" refers to an aryldene group as defined herein in which the aryl ring is substituted with one or two alkyl groups. "Substituted alkarylene" refers to an alkarylene as defined herein in which the aryldene group is further substituted as defined herein for aryl.

[0042] "Aralkylene" refers to -alkyl-arylene- or arylene-alkyl, for example, -C1-C2 alkyl-arylene-, -arylene-C1-C2 alkyl-, or -C1-C2 alkyl-arylene-C1-C2 alkyl- groups, where arylene is as defined herein. "Substituted aralkylene" refers to aralkylene as defined herein, where the aralkylene group is substituted as defined herein for aryl. "Substituted C1-C2 alkyl" refers to a C1-C2 alkyl group substituted as defined herein for alkyl.

[0043] "Arylalkylene" refers to -alkyl-arylene- or arylene-alkyl, for example, -C1-C2 alkyl-arylene-, -arylene-C1-C2 alkyl-, or -C1-C2 alkyl-arylene-C1-C2 alkyl- groups, where arylene is as defined herein. "Substituted arylalkylene" refers to arylalkylene as defined herein, where the arylalkylene group is substituted as defined herein for aryl. "Substituted C1-C2 alkyl" refers to a C1-C2 alkyl group substituted as defined herein for alkyl.

[0044] "Carboxyl" or "carboxy" refers to -C(O)OH or -COOH.

[0045] As used herein, the term "cycloalkyl" refers to a saturated cyclic hydrocarbon, unless otherwise specified. In certain embodiments, the cycloalkyl group can be saturated, and / or bridged, and / or unbridged, and / or a fused bicyclic group. In certain embodiments, the cycloalkyl group contains 3 to 10 carbon atoms (i.e., C3-C 10 cycloalkyl). In some embodiments, cycloalkyl is 3 to 15 carbons (C 3-15 ), 3 to 10 carbons (C 3-10 )、3 to 7 carbons (C3-7 ) or having 3 to 6 carbons (C3-C6) (i.e., “lower cycloalkyl”). In certain embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, cycloheptyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, decalinyl, or adamantyl.

[0046] As used herein, the term “cycloalkylene” refers to a divalent cycloalkyl group as defined herein. In certain embodiments, the cycloalkylene group is cyclopropylene [Chemical formula] and the like. Lower cycloalkylene refers to C3-C6-cycloalkylene.

[0047] As used herein, the term “cycloalkylalkyl” refers to an alkyl group as defined herein substituted with one or two cycloalkyls as defined herein, unless otherwise expressly indicated.

[0048] As used herein, the term “ester” refers to -C(O)OR or -COOR, where R is alkyl as defined herein.

[0049] The term “haloalkyl” refers to an alkyl group as defined herein substituted with one or more halogen atoms (e.g., in some embodiments, 1, 2, 3, 4, or 5) independently selected.

[0050] The term "heteroalkyl" refers to an alkyl as defined herein in which one or more carbon atoms are replaced by heteroatoms. As used herein, "heteroalkenyl" refers to an alkenyl as defined herein in which one or more carbon atoms are replaced by heteroatoms. As used herein, "heteroalkynyl" refers to an alkynyl as defined herein in which one or more carbon atoms are replaced by heteroatoms. Suitable heteroatoms include, but are not limited to, nitrogen (N), oxygen (O), and sulfur (S) atoms. Heteroalkyl, heteroalkenyl, and heteroalkynyl are optionally substituted. Examples of heteroalkyl moieties include, but are not limited to, aminoalkyl, sulfonylalkyl, and sulfinylalkyl. Examples of heteroalkyl moieties also include, but are not limited to, methylamino, methylsulfonyl, and methylsulfinyl. "Substituted heteroalkyl" refers to a heteroalkyl substituted with one, two, or three groups independently selected from halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy. In some embodiments, a heteroalkyl group may contain 1, 2, 3, or 4 heteroatoms. One of ordinary skill in the art will recognize that 4-membered heteroalkyl generally contains one or two heteroatoms, 5- or 6-membered heteroalkyl generally contains 1, 2, or 3 heteroatoms, and 7- to 10-membered heteroalkyl may generally contain 1, 2, 3, or 4 heteroatoms.

[0051] The term "heteroalkylene" as used herein refers to a divalent heteroalkyl as defined herein. "Substituted heteroalkylene" refers to a divalent heteroalkyl as defined herein substituted as described for heteroalkyl.

[0052] The term "heterocycloalkyl" refers to a monovalent, monocyclic, or polycyclic non-aromatic ring system, where one or more of the ring atoms are heteroatoms independently selected from oxygen (O), sulfur (S), and nitrogen (N) (e.g., a nitrogen atom or sulfur atom may optionally be oxidized, and a nitrogen atom may optionally be quaternized), and the remaining ring atoms of the non-aromatic ring are carbon atoms. In certain embodiments, heterocycloalkyl is a monovalent, monocyclic, or polycyclic fully saturated ring system. In certain embodiments, the heterocycloalkyl group has 3 to 20, 3 to 15, 3 to 10, 3 to 8, 4 to 7, 4 to 11, or 5 to 6 ring atoms. Heterocycloalkyl can be attached to the core structure at any heteroatom or carbon atom that results in the formation of a stable compound. In certain embodiments, heterocycloalkyl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, may include fused or bridged ring systems, a nitrogen atom or sulfur atom may optionally be oxidized, and / or a nitrogen atom may optionally be quaternized. In some embodiments, heterocycloalkyl radicals include, but are not limited to, 2,5-diazabicyclo[2.2.2]octanyl, decahydroisoquinolinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl, furanonyl, imidazolidinyl, imidazolinyl, indolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4-piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl, tetrahydroquinolinyl, and 1,3,5-trithianyl. In certain embodiments, heterocycloalkyl may also be optionally substituted as described herein.In certain embodiments, the heterocycloalkyl is substituted with one, two or three groups independently selected from halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, oxo, cyano, and alkoxy. In some embodiments, the heterocycloalkyl group may contain one, two, three, or four heteroatoms. One of ordinary skill in the art will recognize that 4-membered heterocycloalkyl generally contains one or two heteroatoms, 5- or 6-membered heterocycloalkyl generally contains one, two or three heteroatoms, and 7- to 10-membered heterocycloalkyl may generally contain one, two, three, or four heteroatoms.

[0053] "Heterocycloalkylene" refers to a divalent heterocycloalkyl as defined herein.

[0054] The term "heteroaryl" refers to a monovalent monocyclic aromatic group and / or a polycyclic aromatic group, wherein at least one aromatic ring contains one or more heteroatoms independently selected from oxygen, sulfur, and nitrogen within the ring. Each ring of the heteroaryl group may contain one or two oxygen atoms, one or two sulfur atoms, and / or one to four nitrogen atoms, provided that the total number of heteroatoms in each ring is 4 or less and each ring contains at least one carbon atom. In certain embodiments, heteroaryl has 5 to 20, 5 to 15, or 5 to 10 ring atoms. Heteroaryl may be attached to the remainder of the molecule via a nitrogen atom or a carbon atom. In some embodiments, examples of monocyclic heteroaryl groups include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, triazolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, and triazinyl. Examples of bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl, quinazolinyl, thiadiazolopyrimidyl, and thienopyridyl. Examples of tricyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl. In certain embodiments, heteroaryl may also be optionally substituted as described herein. "Substituted heteroaryl" is heteroaryl substituted as defined for aryl.

[0055] The term "heteroarylene" refers to a divalent heteroaryl group as defined herein. "Substituted heteroarylene" is heteroarylene substituted as defined for aryl.

[0056] The term "heteroarylalkylene" refers to -alkyl-heteroarylene- or -heteroarylene-alkyl, for example, -C1-C2alkyl-heteroarylene-, -heteroarylene-C1-C2alkyl-, or -C1-C2alkyl-heteroarylene-C1-C2alkyl-groups, where heteroarylene is as defined herein. "Substituted heteroarylalkylene" refers to heteroarylalkylene as defined herein, in which the heteroarylalkylene group is substituted as aryl is defined herein. "Substituted C1-C2alkyl" refers to a C1-C2alkyl group substituted as alkyl is defined herein.

[0057] As used herein, "oxo" refers to =O.

[0058] As used herein, the term "protecting group" refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent further reaction thereof, or for other purposes, unless otherwise expressly indicated. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis. (See, for example, Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Fourth Edition, 2006, which is incorporated herein by reference).

[0059] "Pharmaceutically acceptable salts" refers to any salts of the compounds provided herein that retain their biological properties and are neither toxic nor otherwise undesirable for pharmaceutical use. Such salts can be derived from a variety of organic and inorganic counterions well known in the art.Examples of such salts include: (1) acid addition salts formed with organic or inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, sulfamic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, hexanoic acid, cyclopentylpropionic acid, glycolic acid, glutaric acid, pyruvic acid, lactic acid, malonic acid, succinic acid, sorbic acid, ascorbic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, picric acid, cinnamic acid, mandelic acid, phthalic acid, lauric acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphoric acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, cyclohexylsulfamic acid, quinic acid, muconic acid, etc.; or (2) salts formed when the acidic proton present in the parent compound is replaced by (a) metal ions, such as alkali metal ions, alkaline earth metal ions, or aluminum ions, or alkali metal or alkaline earth metal hydroxides, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, aluminum hydroxide, lithium hydroxide, zinc hydroxide, and barium hydroxide, or ammonia, or (b) coordinated with organic bases, such as aliphatic, alicyclic, or aromatic organic amines, such as, but not limited to, ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, procaine, N-benzylphenethylamine, N-methylglucamine piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, etc., but are not limited thereto.

[0060] Pharmaceutically acceptable salts further include, by way of example and not limitation, sodium, potassium, calcium, magnesium, ammonium, and tetraalkylammonium salts, etc. When the compound contains a basic functional group, salts of non-toxic organic or inorganic acids are also included, for example, hydrohalic acid salts such as hydrochloride and hydrobromide, sulfate, phosphate, sulfamate, nitrate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate, cyclopentylpropionate, glycolate, glutarate, pyruvate, lactate, malonate, succinate, sorbate, ascorbate, malate, maleate, fumarate, tartrate, citrate, benzoate, 3-(4-hydroxybenzoyl)benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate), ethanesulfonate, 1,2-ethane-disulfonate, 2-hydroxyethanesulfonate, benzenesulfonate (besylate), 4-chlorobenzenesulfonate, 2-naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylate, glucoheptonate, 3-phenylpropionate, trimethylacetate, tert-butylacetate, lauryl sulfate, gluconate, glutamate, hydroxynaphthoate, salicylate, stearate, cyclohexylsulfamate, quinate, muconate, etc.

[0061] The terms "substantially free of" or "substantially in the absence of" with respect to a composition refer to a composition that contains at least 85 wt%, or 90 wt%, in certain embodiments 95 wt%, 98 wt%, 99 wt%, or 100 wt%, or in certain embodiments 95%, 98%, 99%, or 100% of a specified enantiomer or diastereomer of a compound. In certain embodiments, in the methods and compounds provided herein, the compound is substantially free of one of the two enantiomers. In certain embodiments, in the methods and compounds provided herein, the compound is substantially free of one of the two diastereomers. In certain embodiments, in the methods and compounds provided herein, the compound is substantially free of enantiomers (i.e., a racemate, or a 50:50 mixture of the compound).

[0062] Similarly, the term "isolated" with respect to a composition refers to a composition that contains at least 85 wt%, 90 wt%, 95 wt%, 98 wt%, or 99 wt% - 100 wt% of a compound, with the remainder containing other chemical species, enantiomers or diastereomers.

[0063] "Solvate" refers to a compound provided herein, or a salt thereof, that further contains a solvent, in stoichiometric or non-stoichiometric amounts, bound by non-covalent intermolecular forces. When the solvent is water, the solvate is a hydrate.

[0064] "Isotopic composition" refers to the amount of each isotope present for a given atom, and "natural isotopic composition" refers to the isotopic composition or abundance that is present naturally for a given atom. Atoms with a natural isotopic composition may also be referred to herein as "non-enriched" atoms. Unless otherwise specified, atoms of the compounds described herein are meant to represent any stable isotope of that atom. For example, unless otherwise indicated, when a position is specifically designated as hydrogen (H), that position is understood to have hydrogen in its natural isotopic composition.

[0065] "Isotope enrichment" refers to the proportion of a certain amount of a specific isotope incorporated instead of the natural isotope abundance of a given atom within a molecule. For example, if the deuterium (D) enrichment at a given position is 1%, it means that 1% of the molecules in a given sample contain deuterium at that specific position. Since the natural distribution of deuterium is approximately 0.0156%, the deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is approximately 0.0156%. The isotope enrichment of the compounds provided herein can be determined using conventional analytical methods known to those skilled in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

[0066] "Isotope-enriched" refers to an atom having an isotope composition other than the natural isotope composition of that atom. "Isotope-enriched" may also refer to a compound containing at least one atom having an isotope composition other than the natural isotope composition of that atom.

[0067] As used herein, the "alkyl", "alkylene", "alkylamino", "dialkylamino", "cycloalkyl", "aryl", "arylene", "alkoxy", "amino", "carboxyl", "heterocycloalkyl", "heteroaryl", "heteroarylene", "carboxyl", and "amino acid" groups optionally contain deuterium (D) at one or more positions where a hydrogen (H) atom is present, and the deuterium composition of the atom(s) is other than the natural isotope composition.

[0068] Also, as used herein, the "alkyl", "alkylene", "alkylamino", "dialkylamino", "cycloalkyl", "aryl", "arylene", "alkoxy", "amino", "carboxyl", "heterocycloalkyl", "heteroaryl", "heteroarylene", "carboxyl", and "amino acid" groups optionally contain an amount of carbon-13 ( 13 C) other than the natural isotope composition.

[0069] As used herein, "EC"50 The term " " refers to the dose, concentration, or amount of a particular test compound that induces a dose-dependent response at 50% of the maximal manifestation of a particular response induced, elicited, or enhanced by the particular test compound.

[0070] As used herein, unless otherwise expressly indicated, "IC 50 " refers to the amount, concentration, or dose of a particular test compound that achieves 50% inhibition of the maximal response in an assay measuring the maximal response.

[0071] As used herein, the terms "subject" and "patient" are used interchangeably. The terms "subject (singular)" and "subjects (plural)" refer to mammals, including animals such as non-primates (e.g., cows, pigs, horses, cats, dogs, rats, and mice) and primates (e.g., monkeys such as cynomolgus monkeys, chimpanzees, and humans), and in certain embodiments, humans. In certain embodiments, the subject is a farm animal (e.g., a horse, a cow, a pig, etc.) or a pet (e.g., a dog or a cat). In certain embodiments, the subject is a human.

[0072] As used herein, the term "therapeutic agent(s)" refers to any agent(s) that can be used for the treatment or prevention of a disorder or one or more of its symptoms. In certain embodiments, the term "therapeutic agent" includes the compounds provided herein. In certain embodiments, a therapeutic agent is a drug that is known to be useful, or has been used, or is currently being used for the treatment or prevention of a disorder or one or more of its symptoms.

[0073] "Therapeutically effective amount" means the amount of a compound or composition that, when administered to a subject for treating a condition, is sufficient for the effect of such treatment for that condition. A "therapeutically effective amount" can vary, inter alia, depending on the compound, the disease or disorder and its severity, and the age, weight, etc. of the subject to be treated.

[0074] "Treating" or "treatment" of any disease or disorder, in certain embodiments, refers to ameliorating a disease or disorder present in a subject. In another embodiment, "treating" or "treatment" includes ameliorating at least one physical parameter that may be difficult to discern in a subject. In yet another embodiment, "treating" or "treatment" includes modulating a disease or disorder, either physically (e.g., stabilization of discernible symptoms) or physiologically (e.g., stabilization of physiological parameters), or both. In yet another embodiment, "treating" or "treatment" includes delaying or preventing the onset of a disease or disorder, or delaying or preventing recurrence of a disease or disorder. In yet another embodiment, "treating" or "treatment" includes reducing or eliminating any of a disease or disorder, or delaying the progression of a disease or disorder, or delaying one or more symptoms of a disease or disorder, or reducing the severity of a disease or disorder, or reducing the severity of one or more symptoms of a disease or disorder.

[0075] As used herein, the term "preventive agent(s)" refers to any agent(s) that can be used for the prevention of a disorder or one or more symptoms thereof. In certain embodiments, the term "preventive agent" includes the compounds provided herein. In certain other embodiments, the term "preventive agent" does not refer to the compounds provided herein. For example, a preventive agent is known to be useful for preventing or interfering with the manifestation, onset, progression, and / or severity of a disorder, or has been used or is currently used for preventing or arresting the manifestation, onset, progression, and / or severity of a disorder.

[0076] As used herein, the expression "preventively effective amount" refers to an amount of a treatment (e.g., a preventive agent) sufficient to effect prevention or reduction of the development, recurrence, or onset of one or more symptoms associated with a disorder, or to enhance or improve the preventive effect(s) of another treatment (e.g., another preventive agent).

[0077] Compounds of formula (LVII) to (LXIV) There are GLP-1 receptor compounds useful for modulating one or more properties of the GLP-1 receptor herein. This compound can be prepared as described herein and used for treatment or diagnosis. In certain embodiments, this treatment is the treatment of a metabolic disease or condition. In certain embodiments, the treatment is the treatment of type 2 diabetes.

[0078] The embodiments described herein include the listed compounds, as well as pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, tautomers, and / or mixtures thereof.

[0079] In certain embodiments, compounds of formula (LVII), or pharmaceutically acceptable salts or stereoisomers thereof are provided herein [Chemical Structure] wherein B 4 is -CH-, -C(R 2 )-, or -N- D 1 is -CH- or -N- D 2 is -CH-, -N-, or -C(CH3)- D 4 is -CH- or -N- W is N, CR 14 , or C When W is CR 14 , the adjacent dashed line represents a single bond When W is C, the adjacent dashed line represents a double bond or L 2 is -C(H)= and L 1 is selected from the group consisting of -O-, -CH2-, -NH-, -N(Me)-, -N(Et)-, -OCH2-, -OC(H,Me)-, -CH2O-, -CH2NH-, -NHCH2-, -N(Me)CH2-, and -SO2NH- L 2is selected from the group consisting of a bond, -C(O)-, -CH2-, -C(H)=, SO2-, -O-, -NH-, -N(Me)-, and

Chem.

Chem.

[0080] In certain embodiments, the compound of formula (LVII) is selected from compounds 554, 566, 567, 595, 597, 602 - 611, 613, 615 - 617, 619, 620, 622, 624 - 632, and 634 - 636 of Table 2.

[0081] In certain embodiments, a compound of formula (LVIII), or a pharmaceutically acceptable salt or stereoisomer thereof is provided herein,

Chemical Structure

Chemical formula

Chemical formula

[0082] In certain embodiments, when B 4 is -C- and R 3 is -CH2F, the compound described by formula (LVIII) is

Chemical formula

[0083] In certain embodiments, when B 4 is -N- and R 3 is -CH2F, the compound described by formula (LVIII) is

Chemical formula

[0084] In certain embodiments, the compound of formula (LVIII) is selected from compounds 555, 557, 586, 587, and 599 of Table 2.

[0085] In certain embodiments, a compound of formula (LIX), or a pharmaceutically acceptable salt or stereoisomer thereof, is provided herein,

Chemical formula

Chemical formula

Chem.

[0086] In certain embodiments, the compound of formula (LIX) is compound 571 of Table 2.

[0087] In certain embodiments, a compound of formula (LX), or a pharmaceutically acceptable salt or stereoisomer thereof is provided herein,

Chem.

Chemical formula

Chemical formula

[0088] In certain embodiments, the compound of Formula (LX) is selected from compounds 570, 575, 579, 582, 583, 584, 588, 589-592, 600, 601, 612, 618, and 621 in Table 2.

[0089] In certain embodiments, provided herein is a compound of formula (LXIII), or a pharmaceutically acceptable salt or stereoisomer thereof: [ka] During the ceremony, D 1 is -CH- or -N-, D 2 is -CH-, -N-, or -C(CH3)-, D 4 is -CH- or -N-, L 2 is selected from the group consisting of a bond, -C(O)-, -CH2-, -C(H)=, SO2-, -O-, -NH-, -N(Me)-, and

Chemical formula

Chemical formula

[0090] In certain embodiments, the compound of formula (LXI) is compound 614 of Table 2.

[0091] In certain embodiments, a compound of formula (LXII), or a pharmaceutically acceptable salt or stereoisomer thereof is provided herein,

Chemical formula

Chemical formula

Chemical formula

[0092] In certain embodiments, the compound of formula (LXII) is option (a), (b), (c), (d), or (e). In certain embodiments, for option (a), D 1 is -N-, D 2 and D 4 is -CH-, the compound is not one of the following compounds.

Table 3

[0093] In certain embodiments, for option (b), D 1 and D 4 are -CH-, D 2 is -N-. In certain embodiments, for option (c), D 1 and D 4 are -CH-, D 2 is -C(CH3). In certain embodiments, for option (d), D 1 , D 2 , and D 4 are -CH-, R 5 is -H, -CH2OH-CH2COOH, -(CH2)2COOH,

Chemical formula

[0094] In certain embodiments, a compound of any of formulas (LVII - LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein each R 2 and R 3 is H or F.

[0095] In certain embodiments, a compound of any of formulas (LVII - LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein m is 0 and o is 0.

[0096] In certain embodiments, a compound of any of formulas (LVII - LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein W is N or CH.

[0097] In certain embodiments, a compound of any of formulas (LVII, LVIII, LX, and LXII), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein W is C.

[0098] In certain embodiments, a compound of any of formulas (LVII, LVIII, LX, and LXII), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein W is CH.

[0099] In certain embodiments, a compound of any of formulas (LVII, LVIII, LX, and LXII), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein W is N.

[0100] In certain embodiments, a compound of any of formulas (LVII, LVIII, LX, and LXII), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein W is CR 14 is.

[0101] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4It is selected from the group consisting of azetidin-3-yl-methyl, (3R)-azetidin-3-yl-methyl, (3S)-azetidin-3-yl-methyl, (S)-butan-4-yl-1,3-diol, butan-1-yl-one, 1-(cyanomethyl)-cycloprop-1-yl-methyl, 3-(difluoromethyl)oxetan-3-yl-methyl, (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, (1-ethyl-1H-imidazol-5-yl)-methyl, 1-(fluoromethyl)-cycloprop-1-yl-methyl, 3-fluorooxetan-3-yl-methyl, 1-hydroxyl-cycloprop-1-yl-methyl, isoxazol-5-yl-methyl, (3R,4R)-4-methoxytetrahydrofuran-3-yl, (1-methyl-1H-imidazol-5-yl)-methyl, 1-methoxy-cycloprop-1-yl-methyl, methoxyethan-2-yl, 1-(2-methoxyethyl)-cycloprop-1-yl-methyl, {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, oxetan-2-yl-methyl, (2S)-oxetan-2-yl-methyl, oxelan-3-yl-methyl, (3R)-oxelan-3-yl-methyl, 1,3-oxazol-2-yl-methyl, (S)-1,3-oxazol-2-yl-methyl, (R)-1,3-oxazol-2-yl-methyl, 2-oxabicyclo[2.1.1]hex-1-yl-methyl, 1-cyclobutylmethyl, (R)-2-cyclopropoxypropyl, (S)-2-cyclopropoxypropyl, (2R)-2-(difluoromethoxy)propyl, (2S)-2-(difluoromethoxy)propyl, (2S)-oxolan-2-yl-methyl, (1-methoxycyclobutyl)methyl, (2R)-2-(2,2,2-trifluoroethoxy)propyl, (2S)-2-(2,2,2-trifluoroethoxy)propyl, and 2-(2,2,2-trifluoroethoxy)ethyl.

[0102] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is selected from the group consisting of oxetan-2-yl-methyl, (1-ethyl-1H-imidazol-5-yl)-methyl, oxetan-3-yl-methyl, and 1,3-oxazol-2-yl-methyl.

[0103] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is selected from the group consisting of oxetan-2-yl-methyl and (1-ethyl-1H-imidazol-5-yl)-methyl.

[0104] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is oxetan-2-yl-methyl.

[0105] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is (2S)-oxetan-2-yl-methyl.

[0106] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl.

[0107] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is selected from the group consisting of (S)-butan-4-yl-1,3-diol, butan-1-yl-one, 1-(cyanomethyl)-cycloprop-1-yl-methyl, (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, 1-(fluoromethyl)-cycloprop-1-yl-methyl, 1-hydroxyl-cycloprop-1-yl-methyl, isoxazol-5-yl-methyl, (1-methyl-1H-imidazol-5-yl)-methyl, 1-methoxy-cycloprop-1-yl-methyl, methoxyethan-2-yl, 1-(2-methoxyethyl)-cycloprop-1-yl-methyl, 2-oxabicyclo[2.1.1]hex-1-yl-methyl, 1-cyclobutylmethyl, (R)-2-cyclopropoxypropyl, (S)-2-cyclopropoxypropyl, (2R)-2-(difluoromethoxy)propyl, (2S)-2-(difluoromethoxy)propyl, (2S)-oxolan-2-yl-methyl, (1-methoxycyclobutyl)methyl, (2R)-2-(2,2,2-trifluoroethoxy)propyl, (2S)-2-(2,2,2-trifluoroethoxy)propyl, and 2-(2,2,2-trifluoroethoxy)ethyl.

[0108] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is (S)-butan-4-yl-1,3-diol.

[0109] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl.

[0110] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl.

[0111] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl.

[0112] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is 3-fluorooxetan-3-yl-methyl.

[0113] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl.

[0114] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is 1,3-oxazol-2-yl-methyl.

[0115] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is (S)-1,3-oxazol-2-yl-methyl.

[0116] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is (R)-1,3-oxazol-2-yl-methyl.

[0117] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl.

[0118] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 5 is -COOH or -COOMe.

[0119] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 5 is -COOH.

[0120] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 5 is -CH2COOH.

[0121] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 5 is -(CH2)2COOH.

[0122] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 5 is tetrazolyl.

[0123] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 5 is 1H-1,2,3,4-tetrazol-5-yl.

[0124] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 5 is

Chemical formula

[0125] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 5 is

Chemical formula

[0126] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 5 is -H.

[0127] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 5 is -CH2OH.

[0128] In certain embodiments, a compound of any of formulas (LVII-LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein R 5 is

Chemical formula

[0129] In certain embodiments, when the compound is as described in formula (LVII), (LVIII), (LIX), (LX), or (LXII), L 1 is selected from the group consisting of -NH-, -N(Me)-, -N(Et)-, -OCH2-, -OC(H,Me)-, -CH2O-, -OCH2(cyclopropyl)-, -O-CH2-CH2-, -CH2-O-CH2-, -CH2-O-C((CH3)2), -NHCH2-, -CH2NH-, -N(Me)CH2-, and -SO2NH-.

[0130] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -CH2-, -C(O)-, or -SO2-.

[0131] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is a bond, -C(O)-, -CH2-, -C(H)=, -SO2-, -O-, -CF2-, -CHF-, or -CH(OH)-.

[0132] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -O-.

[0133] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -CH2-.

[0134] In certain embodiments, a compound of formulas (LXII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -O-.

[0135] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 3 is -C(O)-.

[0136] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 3 is -CH2-.

[0137] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 3 is -CH(CH3)-.

[0138] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -CH2O-, and L 2is -CH2- or -CO-.

[0139] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -CH2O-, and L 3 is -C(O)-.

[0140] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -OCH2-, and L 2 is -O-.

[0141] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -CH2O-, and L 2 is -O-.

[0142] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -CH2O-, and L 3 is -CH2-.

[0143] In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -CH2O-, and L 3 is -CH(CH3)-.

[0144] In certain embodiments, there is provided a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 1 is -O-CH2-, and L 2 is -O-, and L 3 is -CH2-.

[0145] In certain embodiments, there is provided a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 1 is -O-CH2-, and L 2 is -O-, and L 3 is -CH(CH3)-.

[0146] In certain embodiments, there is provided a compound of any of formula (LXIII), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 1 is -O-CH2-, and L 2 is -O-, and L 3 is -CH2-.

[0147] In certain embodiments, there is provided a compound of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 1 is -O-CH2-.

[0148] In certain embodiments, there is provided a compound of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 1 is -O-.

[0149] In certain embodiments, there is provided a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 1 is -CH2-.

[0150] In certain embodiments, a compound of any of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -OCH2-.

[0151] In certain embodiments, a compound of any of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -CH2O-.

[0152] In certain embodiments, a compound of any of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -OCH2(cyclopropyl).

[0153] In certain embodiments, a compound of any of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -CH2 - O - CH2-.

[0154] In certain embodiments, a compound of any of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -NH-.

[0155] In certain embodiments, a compound of any of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 1 is -N(Me)-

[0156] In certain embodiments, a compound of any of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L1 is -N(Et)-.

[0157] In certain embodiments, there is provided a compound of any one of formulas (LVII) - (LXIV), a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer, and / or a mixture of stereoisomers, wherein L 1 is -OC(H,Me)-.

[0158] In certain embodiments, there is provided a compound of any one of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer, and / or a mixture of stereoisomers, wherein L 1 is -NHCH2-.

[0159] In certain embodiments, there is provided a compound of any one of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer, and / or a mixture of stereoisomers, wherein L 1 is -N(Me)CH2-.

[0160] In certain embodiments, there is provided a compound of any one of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer, and / or a mixture of stereoisomers, wherein L 1 is -SO2NH-.

[0161] In certain embodiments, there is provided a compound of any one of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer, and / or a mixture of stereoisomers, wherein L 1 is -CH2NH-.

[0162] In certain embodiments of any one of formulas (LVII) - (LXIV), L 1 is -O-, and L 2 is -C(O)-. In certain embodiments of any one of formulas (LVII) - (LXIV), L 1 is -O-, and L 2is -CH2-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(H)=. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -SO2-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -NH-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -N(Me)-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(O)-, L 3 is -CH2-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -CH2-, L 3 is -CH2-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(H)=, L 3 is -CH2-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -SO2-, L 3 is -CH2-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -NH-, L 3 is -CH2-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -N(Me)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -C(O)-, L 3is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), -O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVIII)-(LXII), L 1 is -O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3is H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -O-, L2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 can be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4is azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), it is (3R)-azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-butan-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is butan-1-yl-one. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is isoxazol-5-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), it is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas ((LVII)-(LXII), R 4 is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is in certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -O-. In certain embodiments, a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -N(Me)-.

[0163] In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2is -C(O)-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -C(H)=. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -SO2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -NH-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -N(Me)-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -C(O)-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -CH2-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -C(H)=, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -SO2-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -NH--, and L 3is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2O-, and L 2 is -N(Me)-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2O-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2O-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2O-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2O-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2O-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2O-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -CH2O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -CH2O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -CH2O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -CH2O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -CH2O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R3 is each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 is each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 is each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 is each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 is each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1is -CH2O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any particular embodiment of formulae (LVII) to (LXIV), L 1 is -CH2O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any particular embodiment of formulae (LVII) to (LXIV), L 1 is -CH2O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any particular embodiment of formulae (LVII) to (LXIV), L 1 is -CH2O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 may be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In any particular embodiment of formulae (LVII) to (LXIV), R 4is azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-butan-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), it is butan-1-yl-one. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is isoxazol-5-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is, in certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -NH-. In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -N(Me)-.

[0164] In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -C(O)-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -C(H)=. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -SO2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -NH-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -N(Me)-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -C(O)-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -CH2-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -C(H)=, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -SO2-, and L 3is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -NH-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -N(Me)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -SO2-, L3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1is -OCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -CH2-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -C(H)=, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -SO2-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -NH-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, L2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-Ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-Oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-Oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-Oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -SO2-, L 3is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R3 is each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 can be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In a particular embodiment of any of Formulas (LVII) to (LXIV), R 4 is azetidin-3-yl-methyl. In a particular embodiment of any of Formulas (LVII) to (LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In a particular embodiment of any of Formulas (LVII) to (LXIV), it is (3S)-azetidin-3-yl-methyl. In a particular embodiment of any of Formulas (LVII) to (LXIV), R 4 is (S)-but-4-yl-1,3-diol. In a particular embodiment of any of Formulas (LVII) to (LXIV), R 4 is butan-1-yl-one. In a particular embodiment of any of Formulas (LVII) to (LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of Formulas (LVII) to (LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of Formulas (LVII) to (LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In a particular embodiment of any of Formulas (LVII) to (LXIV), R 4 is isoxazol-5-yl-methyl. In a particular embodiment of any of Formulas (LVII) to (LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In a particular embodiment of any of Formulas (LVII) to (LXIV), R4 is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is, in certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -NH-. In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -N(Me)-.

[0165] In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -C(O)-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -CH2-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -C(H)=. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -SO2-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -NH-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -N(Me)-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -C(O)-, and L 3 is -CH2-. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -CH2-, and L 3is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(H)=, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -SO2-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -SO2-, L 3is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(O)-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -CH2-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(H)=, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2and R 3 are each H, and R 4 is (1 - ethyl - 1H - imidazol - 5 - yl) - methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -NH-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1 - ethyl - 1H - imidazol - 5 - yl) - methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -NH-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1 - ethyl - 1H - imidazol - 5 - yl) - methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -NH-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1 - ethyl - 1H - imidazol - 5 - yl) - methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -NH-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S) - oxetan - 2 - yl - methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -NH-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2and R 3 is each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, and L2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, and R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 can be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is butan-1-yl-one. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is 1 - hydroxyl - cycloprop - 1 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is isoxazol - 5 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (1 - methyl - 1H - imidazol - 5 - yl) - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is 1 - methoxy - cycloprop - 1 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is methoxyethan - 2 - yl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is 1 - (2 - methoxyethyl) - cycloprop - 1 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is {[1 - (1,2 - oxazole - 3 - carbonyl)azetidin - 2 - yl]methyl}. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is {[(2R) - 1 - (1,2 - oxazole - 3 - carbonyl)azetidin - 2 - yl]methyl}. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is {[(2S) - 1 - (1,2 - oxazole - 3 - carbonyl)azetidin - 2 - yl]methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is 2 - oxabicyclo[2.1.1]hex - 1 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (S) - but - 4 - yl - 1,3 - diol. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is 3 - (difluoromethyl)oxetan - 3 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is, in certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -N(Me)-.

[0166] In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -C(O)-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -SO2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -NH-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -N(Me)-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -C(O)-, and L3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -CH2-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -SO2-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -NH-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -N(Me)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(O)-, L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -CH2-, L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -SO2-, L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -NH-, L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -N(Me)-, L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(O)-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -CH2-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3is H, respectively, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3is H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, L2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), it is -N(Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of the formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of the formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 can be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of the formulas (LVII)-(LXIV), R 4 is azetidin-3-yl-methyl. In certain embodiments of any of the formulas (LVII)-(LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In certain embodiments of any of the formulas (LVII)-(LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In certain embodiments of any of the formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of the formulas (LVII)-(LXIV), R 4is butan-1-yl-one. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-butan-4-yl-1,3-diol. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -N(Me)-.

[0167] In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -C(O)-. In certain embodiments of any of Formulas (LVII)-(LXIII), L 1 is -N(Et)-, and L 2 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2is -C(H)=. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Et)-, and L 2 is -SO2-. In certain embodiments of any of Formulas (LVII) to (LXIV), it is -N(Et)-, and L 2 is -NH-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Et)-, and L 2 is -N(Me)-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Et)-, and L 2 is -C(O)-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Et)-, and L 2 is -CH2-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), it is -N(Et)-, and L 2 is -C(H)=, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Et)-, and L 2 is -SO2-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), it is -N(Et)-, and L 2 is -NH-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Et)-, and L 2 is -N(Me)-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Et)-, and L 2 is -C(O)-, and L3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -CH2-, L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIII), L 1 is -N(Et)-, L 2 is -C(H)=, L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -SO2-, L 3 is -CH2-, and R 2 and R 3 [[ID=IS=35]]are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -NH-, L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -N(Me)-, L 3 is -CH2-, and R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -C(O)-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), -N(Et)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -SO2-, L 3is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -C(O)-, L3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -NH-, and L 3 is -CH2-, and R2 and R 3 is each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), -N(Et)-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3is H, respectively, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any particular embodiment of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any particular embodiment of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any particular embodiment of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1may be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is azetidin-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-butan-4-yl-1,3-diol. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is butan-1-yl-one. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is In certain embodiments of any of formulas (LVII)-(LXIV), R 4is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, there is provided a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2is -NH-. In certain embodiments, there are provided compounds of any of formulas (LVII) - (LXIV), their pharmaceutically acceptable salts, tautomers, stereoisomers, and / or mixtures of stereoisomers, wherein L 2 is -N(Me)-.

[0168] In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NHCH2-, and L 2 is -C(O)-. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NHCH2-, and L 2 is -CH2-. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NHCH2-, and L 2 is -C(H)=. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NHCH2-, and L 2 is -SO2-. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NHCH2-, and L 2 is -NH-. In certain embodiments of any of formulas (LVII) - (LXIV), -NHCH2-, and L 2 is -N(Me)-. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NHCH2-, and L 2 is -C(O)-, and L 3 is -CH2-. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NHCH2-, and L 2 is -CH2-, and L 3 is -CH2-. In certain embodiments of any of formulas (LVII) - (LXIV), -NHCH2-, and L 2 is -C(H)=, and L 3is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -NHCH2-, L 2 is -SO2-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -NHCH2-, L 2 is -NH-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -NHCH2-, L 2 is -N(Me)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -NHCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -NHCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -NHCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -NHCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L1 is -NHCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3is H, respectively, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3is H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are H respectively, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 can be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is azetidin-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is butan-1-yl-one. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4is 1 - hydroxyl - cycloprop - 1 - yl - methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is isoxazol - 5 - yl - methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is (1 - methyl - 1H - imidazol - 5 - yl) - methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is 1 - methoxy - cycloprop - 1 - yl - methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is methoxyethan - 2 - yl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is 1 - (2 - methoxyethyl) - cycloprop - 1 - yl - methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is {[1 - (1,2 - oxazole - 3 - carbonyl)azetidin - 2 - yl]methyl}. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is {[(2R) - 1 - (1,2 - oxazole - 3 - carbonyl)azetidin - 2 - yl]methyl}. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is {[(2S) - 1 - (1,2 - oxazole - 3 - carbonyl)azetidin - 2 - yl]methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is 2 - oxabicyclo[2.1.1]hex - 1 - yl - methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is (S) - but - 4 - yl - 1,3 - diol. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4 is 3 - (difluoromethyl)oxetan - 3 - yl - methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), R 4is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is, in certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 [[ID=FIG=20]]is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, there is provided a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -NH-. In certain embodiments, there is provided a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -N(Me)-.

[0169] In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -C(O)-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -C(H)=. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -SO2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -NH-. In certain embodiments of any of Formulas (LVII)-(LXIV), -CH2NH-, and L 2is -N(Me)-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -CH2-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), it is -CH2NH-, L 2 is -C(H)=, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -SO2-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -NH-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -N(Me)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3is H in each case. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are H in each case. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are H in each case. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are H in each case. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are H in each case. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are H in each case, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -CH2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are H in each case, and R 4is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -NH-, L3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2NH-, L2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, -, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 -CH2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 can be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is azetidin-3-yl-methyl. In certain embodiments of any of formulas ((LVII)-(LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is (3S)-azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-butan-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is butan-1-yl-one. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is isoxazol-5-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is [(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, there is provided a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -NH-. In certain embodiments, there is provided a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -N(Me)-.

[0170] In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(O)-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(H)=. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -SO2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -NH-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -N(Me)-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(O)-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -CH2-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(H)=, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -SO2-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -NH-, and L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1is -N(Me)CH2-, L 2 is -N(Me)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Me)CH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Me)CH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Me)CH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Me)CH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Me)CH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -N(Me)CH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3They are each H. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -N(Me)CH2-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -N(Me)CH2-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -N(Me)CH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, L 2 is -C(H)=, L 3 is -CH2-, R2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -CH2-, and L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(H)=, and L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -SO2-, and L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -NH-, and L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -SO2-, and L3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -CH2-, and L3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)CH2-, and L 2is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 can be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is butan-1-yl-one. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is isoxazol-5-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is, in certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, there is provided a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -NH-. In certain embodiments, there is provided a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -N(Me)-.

[0171] In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)- and L 2 is -C(O)-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)- and L 2 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)- and L 2 is -C(H)=. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)- and L 2 is -SO2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)- and L 2 is -NH-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)- and L 2 is -N(Me)-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)- and L 2is -C(O)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -OC(H,Me)-, L 2 is -CH2-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -OC(H,Me)-, L 2 is -C(H)=, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -OC(H,Me)-, L 2 is -SO2-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -OC(H,Me)-, L 2 is -NH-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -OC(H,Me)-, L 2 is -N(Me)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -OC(H,Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -OC(H,Me)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -OC(H,Me)-, L 2is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1is -OC(H,Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1is -OC(H,Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1is -OC(H,Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -CH2-, L 3is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R2 and R 3 is each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, and L 2 is -SO2-, and L 3is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -NH-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OC(H,Me)-, L 2 is -N(Me)-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 can be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is (3S)-azetidin-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-butan-4-yl-1,3-diol. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is butan-1-yl-one. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4is [(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is, in certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments, provided is a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -N(Me)-.

[0172] In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -C(O)-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -C(H)=. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L2 is -SO2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -NH-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -N(Me)-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(O)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -CH2-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(H)=, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -SO2-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -NH-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -N(Me)-, L 3 is -CH2-. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(O)-, L 3 is -CH2-, R2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (2S)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (2S)-oxetan-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -SO2-, L 3is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -SO2NH-, L 2 is -C(O)-, L3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -NH-, and L 3 is -CH2-, and R2 and R 3 is each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (2S)-oxetan-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -SO2NH-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any particular embodiment of formulas (LVII) to (LXIV), L 1 is -SO2NH-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any particular embodiment of formulas (LVII) to (LXIV), L 1 is -SO2NH-, and L 2 is -NH-, and L 3 is -CH^2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any particular embodiment of formulas (LVII) to (LXIV), L 1 is -SO2NH-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is (1-ethyl-1H-imidazol-5-yl)-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 can be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. It should be noted that in the translation, there may be some symbols that need to be adjusted according to the actual typesetting requirements to ensure the accuracy and readability of the text. Here, for the sake of presentation, some symbols are directly retained. For example, the chemical formula-related symbols should be typeset correctly in the actual patent text. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is azetidin-3-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is butan-1-yl-one. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is, in certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, there is provided a compound of any of formulas (LVII) to (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -NH-. In certain embodiments, there is provided a compound of any of formulas (LVII) to (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -N(Me)-.

[0173] In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -O-2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R3 is each H, and R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2and R 3 is H, respectively, and R 4 is oxiran-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -O-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 is H, respectively, and R 4 is oxiran-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -O-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 is H, respectively, and R 4 is oxiran-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -O-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 is H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -O-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 is H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -O-, and L 2is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 may be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is (3R)-azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (S)-butan-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is butan-1-yl-one. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is isoxazol-5-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII) to (LXIV), R 4is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of formulas (LVII)-(LXIV), R4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, there is provided a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -NH-. In certain embodiments, there is provided a compound of any of Formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2 is -N(Me)-.

[0174] In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -C(O)-, and L3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -CH2O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -CH2O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -CH2O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -CH2O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -CH2O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L1 is -CH2O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3is H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is oxolan-3-yl-methyl, and R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2O-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 may be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is, in certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl.

[0175] In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -SO2-, L 3is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -OCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3is H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -OCH2-, and L2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -OCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -OCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -OCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -OCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2and R 3 is each H, and R 4 is oxiran-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is oxiran-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is oxiran-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -C(H)=, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -SO2-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -NH-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -OCH2-, L 2 is -N(Me)-, L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 may be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is butan-1-yl-one. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is isoxazol-5-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is, in certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -NH-. In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -N(Me)-.

[0176] In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1is -NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3is H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NH-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is oxolan-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NH-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is oxolan-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NH-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is oxolan-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NH-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is oxolan-3-yl-methyl, and R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 may be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4 is azetidin-3-yl-methyl. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4 is (S)-butan-4-yl-1,3-diol. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4 is butan-1-yl-one. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4 is isoxazol-5-yl-methyl. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4 is 1-methoxy-cycloprop-1-yl-methyl. In a particular embodiment of any of Formulas (LVII)-(LXIV), R 4is methoxyethan-2-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of formulas (LVII) to (LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, there is provided a compound of any of formulas (LVII) to (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2is -NH-. In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -N(Me)-.

[0177] In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -NH-, L 3is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3is H, respectively, and R 4 is oxiran-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is oxiran-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is oxiran-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is oxiran-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, and L 2is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -N(Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -N(Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -N(Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl, R 5is -COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -N(Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -N(Me)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -N(Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), -N(Me)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 may be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is (S)-butan-4-yl-1,3-diol. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is butan-1-yl-one. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is isoxazol-5-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is 1-methoxy-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4is methoxyethan-2-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of formulas (LVII) - (LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, there is provided a compound of any of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein L 2is -NH-. In certain embodiments, a compound of any of formulas (LVII) to (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -N(Me)-.

[0178] In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Et)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Et)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Et)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Et)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -N(Me)-, L 2 is -NH-, L 3is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Me)-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L1 is -N(Et)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -N(Et)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -N(Et)-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -N(Et)-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -N(Et)-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -N(Et)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3is H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -N(Et)-, L 2 is -SO2-, L 3 is -CH2-, R2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -N(Et)-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 can be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In a specific embodiment of any of the formulas (LVII) to (LXIV), R 4 is azetidin-3-yl-methyl. In a specific embodiment of any of the formulas (LVII) to (LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In a specific embodiment of any of the formulas (LVII) to (LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In a specific embodiment of any of the formulas (LVII) to (LXIV), R 4 is (S)-but-4-yl-1,3-diol. In a specific embodiment of any of the formulas (LVII) to (LXIV), R 4 is butan-1-yl-one. In a specific embodiment of any of the formulas (LVII) to (LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In a specific embodiment of any of the formulas (LVII) to (LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In a specific embodiment of any of the formulas (LVII) to (LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In a specific embodiment of any of the formulas (LVII) to (LXIV), R 4 is isoxazol-5-yl-methyl. In a specific embodiment of any of the formulas (LVII) to (LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In a specific embodiment of any of the formulas (LVII) to (LXIV), R 4is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is, in certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII) to (LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -NH-. In certain embodiments, a compound of any of formulas (LVII)-(LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -N(Me)-.

[0179] In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L1 is -NHCH2-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NHCH2-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NHCH2-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NHCH2-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan - 3 - yl - methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -NHCH2-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan - 3 - yl - methyl, R 5is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3is H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are H, respectively, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of Formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -NHCH2-, and L 2 is -SO2-, and L 3 is -CH2-, and R2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NHCH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NHCH2-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is oxiran-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NHCH2-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NHCH2-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NHCH2-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NHCH2-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NHCH2-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII) to (LXIV), L 1 is -NHCH2-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 may be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is (S)-butan-4-yl-1,3-diol. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is butan-1-yl-one. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is isoxazol-5-yl-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In a particular embodiment of any of formulas (LVII) to (LXIV), R 4is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is, in certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (LVII)-(LXIV), R 4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, a compound of any of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -NH-. In certain embodiments, a compound of any of formulas (LVII) - (LXIV), or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof is provided, wherein L 2 is -N(Me)-.

[0180] In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, and R 4 is oxolan-3-yl-methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, and R 4is oxiran-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), L1 is -CH2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3 - oxazol - 2 - yl - methyl. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan - 3 - yl - methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan - 3 - yl - methyl, R 5is -COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -SO2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -NH-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxiran-3-yl-methyl, R 5 is -COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3is H, respectively, and R 4 is 1,3 - oxazol - 2 - yl - methyl, and R 5 is - COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is - CH2NH -, and L 2 is - CH2 -, and L 3 is - CH2 -, and R 2 and R 3 are H, respectively, and R 4 is 1,3 - oxazol - 2 - yl - methyl, and R 5 is - COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is - CH2NH -, and L 2 is - C(H)=, and L 3 is - CH2 -, and R 2 and R 3 are H, respectively, and R 4 is 1,3 - oxazol - 2 - yl - methyl, and R 5 is - COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is - CH2NH -, and L 2 is - SO2 -, and L 3 is - CH2 -, and R 2 and R 3 are H, respectively, and R 4 is 1,3 - oxazol - 2 - yl - methyl, and R 5 is - COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is - CH2NH -, and L 2 is - NH -, and L 3 is - CH2 -, and R 2 and R 3 are H, respectively, and R 4 is 1,3 - oxazol - 2 - yl - methyl, and R 5 is - COOH. In certain embodiments of any of Formulas (LVII) - (LXIV), L 1 is - CH2NH -, and L2 is -N(Me)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is 1,3-oxazol-2-yl-methyl, R 5 is -COOH. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(O)-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -CH2-, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -C(H)=, L 3 is -CH2-, R 2 and R 3 are each H, R 4 is oxolan-3-yl-methyl, R 5 is tetrazolyl, e.g., 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, L 2 is -SO2-, L 3 is -CH2-, R2 and R 3 is each H, and R 4 is oxiran-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is oxiran-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is oxiran-3-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -C(O)-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -CH2-, and L 3 is -CH2-, and R 2 and R 3 is each H, and R4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -C(H)=, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -SO2-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -NH-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4 is 1,3-oxazol-2-yl-methyl, and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of formulas (LVII)-(LXIV), L 1 is -CH2NH-, and L 2 is -N(Me)-, and L 3 is -CH2-, and R 2 and R 3 are each H, and R 4is 1,3-oxazol-2-yl-methyl and R 5 is tetrazolyl, for example, 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R 1 can be selected from H, Cl, F, Me, -CF3, -OMe, -CN, -C(O)NMe2, alkyl, propyl, isopropyl, and cyclopropyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is (3R)-azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is (3S)-azetidin-3-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is butan-1-yl-one. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is 1-(fluoromethyl)-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is 1-hydroxyl-cycloprop-1-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is isoxazol-5-yl-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4 is (1-methyl-1H-imidazol-5-yl)-methyl. In a particular embodiment of any of formulas (LVII)-(LXIV), R 4is 1-methoxy-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is methoxyethan-2-yl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 2-oxabicyclo[2.1.1]hex-1-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is (S)-but-4-yl-1,3-diol. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of formulas (LVII)-(LXIV), R 4is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodimen...

Claims

1. A compound according to formula (LVII), (LVIII), (LIX), (LX), (LXI), or (LXII), or compounds 552, 553, 558, 561, 562, 572, 573, 576, 578, 581, 640, and 641, or pharmaceutically acceptable salts or stereoisomers thereof, wherein 【Chemical 1】 wherein When the compound is as described in formula (LVII), B ４ is -CH-, -C(R ２ )-, or -N-, and D １ is -CH- or -N-, D ２ is -CH-, -N-, -C(CH ３ )-, and D ４ is -CH- or -N-, W is N, CR １４ , or C, and when W is CR １４ , the adjacent dashed line indicates a single bond, and when W is C, the adjacent dashed line indicates a double bond, or L ２ is -C(H)= L １ is selected from the group consisting of -O-, -CH ２ -, -NH-, -N(Me)-, -N(Et)-, -OCH ２ -, -OC(H,Me)-, -CH ２ O-, -NHCH ２ -, -CH ２ NH-, -N(Me)CH ２ -, and -SO ２ NH- and is selected from the group consisting of: L ２ is a bond, -C(O)-, -CH ２ -, -C(H)=, SO ２ -, -O-, -NH-, -N(Me)-, and [Chemical Formula 2] is selected from the group consisting of L ３ is -CH ２ -, -C(O)-, or -CH(CH ３ )- and Each R １ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and R １１ R １２ NCO—, Each R ２ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and R １１ R １２ NCO−, Each R ３ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azide, alkoxy, haloalkoxy, and R １１ R １２ NCO−, R ４ is selected from the group consisting of alkyl, substituted alkyl, unsubstituted arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkyl, and substituted heterocycloalkyl, R ５ is -H, -CH ２ OH, -COOH, -CH ２ COOH, -(CH ２ ) ２ COOH, -COCF ３ , -C(OH)CF ３ , -CONHCN, -CONHOH, CONHOMe, -CONHSO ２ N(Me) ２ , -PO ３ H ２ , -PO(Me)(OH), -SO ３ H, -SO ２ NH ２ , -SO ２ NHMe, -B(OH) ２ , [Chemical Formula 3] is selected from the group consisting of Each R １１ is hydrogen or alkyl, Each R １２ is hydrogen or alkyl, R １３ is hydrogen, alkyl, or - cyclopropyl, and R １４ is hydrogen or alkyl, and n is an integer from 0 to 4, m is an integer from 0 to 3, o is an integer from 0 to 4, When the compound is as described in formula (LVIII), R ３ is independently, -CH ２ CH ３ -, -CH ２ F, -CH ２ CN, and -CF ３ selected from the group consisting of, and all other variables are as in formula (LVII), B ４ is -C-, R ３ is -CH ２ F, when the compound is 【Chemical 4】 Rather than B ４ is -N-, and R ３ is -CH ２ F, when the compound is 【Chemical Formula 5】 and not when the compound is as described in formula (LIX), the variables are as in formula (LVII), When the compound is as described in formula (LX), R ４ is (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, [Chemical Formula 6] selected from the group consisting of, R ７ is, -CH ２ F or -CHF ２ and all other variables are as in formula (LVII), when the compound is as described in formula (LXI), the other variables are as in formula (LVII), when the compound is as described in formula (LXII), it is any one of (a), (b), (c), (d), or (e), (a) D １ is -N-, and D ２ and D ４ is -CH-, the compound is not the following 【Table 1】 are all other variables as in formula (LVII), or or (b) D １ and D ４ is —CH—, D ２ is —N—, and all other variables are as in formula (LVII), or or (c) D １ is -CH-, and D ４ is -CH- or -N-, and D ２ is -C(CH ３ ) and all other variables are as in formula (LVII), or or (d) D １ , D ２ , and D ４ is -CH- or -N-, and D １ , D ２ , and D ４ of which 0 or 1 is -N-, and R ５ is H, CH ２ OH, -CH ２ COOH, -(CH ２ ) ２ COOH, 【Chemical Formula 7】 selected from the group consisting of, R １３ is, -CH ３ or -cyclopropyl, and all other variables are as in formula (LVII), or or (e) D １ , D ２ , and D ４ is -CH- or -N-, and D １ , D ２ , and D ４ among which 0 or 1 is -N-, and L ３ is -CH(CH ３ )-, and all other variables are as in formula (LVII), or 【Table 2-1】 【Table 2-2】 【Table 2-3】 When the compound is as described in formula (LVII), (LVIII), (LIX), (LX), or (LXI), L １ is selected from the group consisting of -NH-, -N(Me)-, -N(Et)-, -OCH ２ -, -OC(H,Me)-, -CH ２ O-, -OCH ２ (cyclopropyl)-, -O-CH ２ -CH ２ -, -CH ２ -O-CH ２ -, -CH ２ -O-C((CH ３ ) ２ )-, -NHCH ２ -, -CH ２ NH-, -N(Me)CH ２ (-), and -SO ２ NH-; a compound as described in formula (LVII), (LVIII), (LIX), (LX), (LXI), or (LXI), or compound 552, 553, 558, 561, 562, 572, 573, 576, 578, 581, 640, and 641, or a pharmaceutically acceptable salt or stereoisomer thereof.

2. A compound according to formula LXIII, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein 【Chemical Formula 8】 wherein D １ is -CH- or -N-, D ２ is -CH-, -N-, -C(CH ３ )-, and D ４ is -CH- or -N-, W is N, CR １４ , or C, and when W is CR １４ , the adjacent dashed line represents a single bond, and when W is C, the adjacent dashed line represents a double bond, or L ２ is -C(H)= L １ is selected from the group consisting of -O-, -CH ２ -, -NH-, -N(Me)-, -N(Et)-, -OCH ２ -, -OC(H,Me)-, -CH ２ O-, -NHCH ２ -, -CH ２ NH-, -N(Me)CH ２ -, and -SO ２ NH- and is selected from the group consisting of L ２ is a bond, -C(O)-, -CH ２ -, -C(H)=, SO ２ -, -O-, -NH-, -N(Me)-, and 【Chemical Formula 9】 is selected from the group consisting of L ３ is -CH ２ -, -C(O)-, or -CH(CH ３ )- and Each R １ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and R １１ R １２ NCO−, Each R ２ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and R １１ R １２ NCO−, Each R ３ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and R １１ R １２ NCO−, R ４ is (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, 【Chemical Formula 10】 is selected from the group consisting of R ５ is -H, -CH ２ OH, -COOH, -CH ２ COOH, -(CH ２ ) ２ COOH, -COCF ３ , -C(OH)CF ３ , -CONHCN, -CONHOH, CONHOMe, -CONHSO ２ N(Me) ２ , -PO ３ H ２ , -PO(Me)(OH), -SO ３ H, -SO ２ NH ２ , -SO ２ NHMe, -B(OH) ２ , 【Chemical 11】 is selected from the group consisting of R ７ is -CH ２ F or -CHF ２ and Each R １１ is hydrogen or alkyl, Each R １２ is hydrogen or alkyl, and R １３ is hydrogen, alkyl, or -cyclopropyl, and R １４ is hydrogen or alkyl, n is an integer from 0 to 4, m is an integer from 0 to 3, o is an integer from 0 to 4, the compound according to formula LXIII, or a pharmaceutically acceptable salt or stereoisomer thereof.

3. A compound according to formula LXIV, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein 【Chemical 12】 wherein D １ is -CH- or -N-, D ２ is -CH-, -N-, -C(CH ３ )-, and D ４ is -CH- or -N-, W is N, CR １４ , or C, and when W is CR １４ , the adjacent dashed line indicates a single bond, and when W is C, the adjacent dashed line indicates a double bond, or L ２ is -C(H)=, L １ is selected from the group consisting of -O-, -CH ２ -, -NH-, -N(Me)-, -N(Et)-, -OCH ２ -, -OC(H,Me)-, -CH ２ O-, -NHCH ２ -, -CH ２ NH-, -N(Me)CH ２ -, and -SO ２ NH- L ２ is a bond, -C(O)-, -CH ２ -, -C(H)=, SO ２ -, -O-, -NH-, -N(Me)-, and 【Chemical Formula 13】 is selected from the group consisting of L ３ is -CH ２ -, -C(O)-, or -CH(CH ３ )- and Each R １ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and R １１ R １２ NCO−, Each R ２ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azide, alkoxy, haloalkoxy, and R １１ R １２ NCO−, Each R ３ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azide, alkoxy, haloalkoxy, and R １１ R １２ NCO−, R ４ is alkyl, substituted alkyl, unsubstituted arylalkylene, substituted arylalkylene, heteroalkyl, substituted heteroalkyl, unsubstituted heteroarylalkylene, substituted heteroarylalkylene, unsubstituted heterocycloalkyl, or substituted heterocycloalkyl, and R ５ is H, CH ２ OH, -CH ２ COOH, -(CH ２ ) ２ COOH, 【Chemical Formula 14】 is selected from the group consisting of R ７ is -CH ２ F or -CHF ２ and Each R １１ is hydrogen or alkyl, Each R １２ is hydrogen or alkyl, R １３ is hydrogen, alkyl, or -cyclopropyl, and R １４ is hydrogen or alkyl, n is an integer from 0 to 4, m is an integer from 0 to 3, o is an integer from 0 to 4, the compound according to formula LXIV, or a pharmaceutically acceptable salt or stereoisomer thereof.

4. Each R ２ and R ３ is H or F, a compound according to any one of the preceding claims.

5. The compound according to any one of the preceding claims, wherein m is 0 and o is 0.

6. The compound according to any one of the preceding claims, wherein W is N or CH.

7. The compound according to any one of the preceding claims, wherein W is C.

8. The compound according to any one of the preceding claims, wherein W is CH.

9. The compound according to any one of the preceding claims, wherein W is N.

10. D ４ The compound according to any one of the preceding claims, wherein D is -CH-.

11. R ４ is azetidin-3-yl-methyl, (3R)-azetidin-3-yl-methyl, (3S)-azetidin-3-yl-methyl, (S)-butan-4-yl-1,3-diol, butan-1-yl-one, 1-(cyanomethyl)-cycloprop-1-yl-methyl, 3-(difluoromethyl)oxetan-3-yl-methyl, (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, (1-ethyl-1H-imidazol-5-yl)-methyl, 1-(fluoromethyl)-cycloprop-1-yl-methyl, 3-fluorooxetan-3-yl-methyl, 1-hydroxyl-cycloprop-1-yl-methyl, isoxazol-5-yl-methyl, (3R,4R)-4-methoxytetrahydrofuran-3-yl, (1-methyl-1H-imidazol-5-yl)-methyl, 1-methoxy-cycloprop-1-yl-methyl, methoxyethan-2-yl, 1-(2-methoxyethyl)-cycloprop-1-yl-methyl, {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, oxetan-2-yl-methyl, (2S)-oxetan-2-yl-methyl, oxelan-3-yl-methyl, (3R)-oxelan-3-yl-methyl, 1,3-oxazol-2-yl-methyl, (S)-1,3-oxazol-2-yl-methyl, (R)-1,3-oxazol-2-yl-methyl, 2-oxabicyclo[2.1.1]hex-1-yl-methyl, 1-cyclobutylmethyl, (R)-2-cyclopropoxypropyl, (S)-2-cyclopropoxypropyl, (2R)-2-(difluoromethoxy)propyl, (2S)-2-(difluoromethoxy)propyl, (2S)-oxolan-2-yl-methyl, (1-methoxycyclobutyl)methyl, (2R)-2-(2,2,2-trifluoroethoxy)propyl, (2S)-2-(2,2,2-trifluoroethoxy)propyl, and 2-(2,2,The compound according to any one of the preceding claims, selected from the group consisting of 2-trifluoroethoxy)ethyl.,

12. R ４ is a compound according to any one of the preceding claims, wherein R is selected from the group consisting of (1-ethyl-1H-imidazol-5-yl)-methyl, oxetan-2-yl-methyl, (2S)-oxetan-2-yl-methyl, oxiran-3-yl-methyl, (3R)-oxiran-3-yl-methyl, and 1,3-oxazol-2-yl-methyl.

13. R ４ is a compound according to any one of the preceding claims, selected from the group consisting of (S)-butan-4-yl-1,3-diol, 3-(difluoromethyl)oxetan-3-yl-methyl, (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, (1-ethyl-1H-imidazol-5-yl)-methyl, 3-fluorooxetan-3-yl-methyl, (3R,4R)-4-methoxytetrahydrofuran-3-yl, oxetan-2-yl-methyl, (2S)-oxetan-2-yl-methyl, 1,3-oxazol-2-yl-methyl, (S)-1,3-oxazol-2-yl-methyl, (R)-1,3-oxazol-2-yl-methyl, 2-oxabicyclo[2.1.1]hex-1-yl-methyl, 1-cyclobutylmethyl, (R)-2-cyclopropoxypropyl, (S)-2-cyclopropoxypropyl, (2R)-2-(difluoromethoxy)propyl, (2S)-2-(difluoromethoxy)propyl, (2S)-oxolan-2-yl-methyl, (1-methoxycyclobutyl)methyl, (2R)-2-(2,2,2-trifluoroethoxy)propyl, (2S)-2-(2,2,2-trifluoroethoxy)propyl, and 2-(2,2,2-trifluoroethoxy)ethyl.

14. R ４ The compound according to any one of the preceding claims, wherein R is (S)-butan-4-yl-1,3-diol.

15. R ４ The compound according to any one of the preceding claims, wherein R is 3-(difluoromethyl)oxetan-3-ylmethyl.

16. R ４ The compound according to any one of the preceding claims, wherein R is (1-ethyl-1H-imidazol-5-yl)-methyl.

17. R ４ The compound according to any one of the preceding claims, wherein R is 3 - fluorooxetan - 3 - yl - methyl.

18. R ４ The compound according to any one of the preceding claims, wherein R is (3R,4R)-4-methoxytetrahydrofuran-3-yl.

19. R ４ The compound according to any one of the preceding claims, wherein R is oxetan-2-yl-methyl.

20. R ４ The compound according to any one of the preceding claims, wherein R is (2S)-oxetan-2-yl-methyl.

21. R ４ The compound according to any one of the preceding claims, wherein R is 1,3-oxazol-2-yl-methyl.

22. R ４ The compound according to any one of the preceding claims, wherein R is (S)-1,3-oxazol-2-yl-methyl.

23. R ４ The compound according to any one of the preceding claims, wherein R is (R)-1,3-oxazol-2-yl-methyl.

24. R ４ The compound according to any one of the preceding claims, wherein R is 2-oxabicyclo[2.1.1]hex-1-ylmethyl.

25. R ４ The compound according to any one of the preceding claims, wherein R is ((R)-1,1-dioxidothietan-2-yl)methyl.

26. R ４ The compound according to any one of the preceding claims, wherein R is ((S)-1,1-dioxidothietan-2-yl)methyl.

27. R ４ The compound according to any one of the preceding claims, wherein R is 1-cyclobutylmethyl.

28. R ４ The compound according to any one of the preceding claims, wherein R is (R)-2-cyclopropoxypropyl.

29. R ４ The compound according to any one of the preceding claims, wherein R is (S)-2-cyclopropoxypropyl.

30. R ４ The compound according to any one of the preceding claims, wherein R is (2R)-2-(difluoromethoxy)propyl.

31. R ４ The compound according to any one of the preceding claims, wherein R is (2S)-2-(difluoromethoxy)propyl.

32. R ４ The compound according to any one of the preceding claims, wherein R is (2S)-oxolan-2-yl-methyl.

33. R ４ The compound according to any one of the preceding claims, wherein R is (1-methoxycyclobutyl)methyl.

34. R ４ The compound according to any one of the preceding claims, wherein R is (2R)-2-(2,2,2-trifluoroethoxy)propyl.

35. R ４ The compound according to any one of the preceding claims, wherein R is (2S)-2-(2,2,2-trifluoroethoxy)propyl.

36. R ４ The compound according to any one of the preceding claims, wherein R is 2-(2,2,2-trifluoroethoxy)ethyl.

37. R ５ The compound according to any one of the preceding claims, wherein R is -COOH.

38. R ５ is 【Chemical 15】 A compound according to any one of the preceding claims.

39. R ５ is 【Chemical 16】 and in the formula, R １３ is -CH ３ or -cyclopropyl, and the compound according to any one of the preceding claims.

40. R ５ is -CH ２ COOH, a compound according to any one of the preceding claims.

41. R ５ is -(CH ２ ) ２ COOH, and the compound according to any one of the preceding claims.

42. R ５ The compound according to any one of the preceding claims, wherein R is -H.

43. R ５ is -CH ２ OH, the compound according to any one of the preceding claims.

44. R ５ is 【Chemical 17】 A compound according to any one of the preceding claims.

45. L ２ The compound according to any one of claims 1 to 44, wherein L is -O-.

46. L ３ is -CH ２ -, the compound according to any one of claims 1 to 45.

47. L ３ is -CH(CH ３ )-, the compound according to any one of claims 1 to 45.

48. L １ is -CH ２ O-, and L ２ is -O-, the compound according to any one of claims 1 to 47.

49. L １ is -OCH ２ -, and L ２ is -O-, the compound according to any one of claims 1 to 47.

50. L １ is -CH ２ O-, and L ３ is CH ２ -, a compound according to any one of claims 1 to 47.

51. L １ is -CH ２ O-, and L ３ is -CH(CH ３ )), the compound according to any one of claims 1 to 47.

52. L １ The compound according to any one of claims 1 to 51, wherein L is -O-.

53. L １ is -CH ２ O-, the compound according to any one of claims 1 to 50, 51, 53, and 54.

54. L １ is -OCH ２ -, the compound according to any one of claims 1 to 50 and 52.

55. A compound selected from any of the compounds in Table 1 and Table 2, or a pharmaceutically acceptable salt or solvate thereof.

56. A pharmaceutical composition comprising a compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

57. A method for treating a metabolic disease or disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 55, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition according to claim 56.

58. A compound according to any one of claims 1 to 55, or the pharmaceutical composition according to claim 56, for use in therapy.

59. A compound according to any one of claims 1 to 55, or the pharmaceutical composition according to claim 56, for use in the treatment of a metabolic disease or disorder.

60. Use of a compound according to any one of claims 1 to 56, or the pharmaceutical composition according to claim 56, in the manufacture of a medicament for the treatment of a metabolic disease or disorder.

Images